An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)

Fader, Amanda N.; Starks, David; Gehrig, Paola A.; Secord, Angeles Alvarez; Frasure, Heidi E.; O’Malley, David M.; Tuller, Erin; Rose, Peter G.; Havrilesky, Laura J.; Moore, Kathleen N.; Huh, Warner K.; Axtell, Allison E.; Kelley, Joseph L.; Zanotti, Kristine

doi:10.1016/j.ygyno.2009.07.030

Cited by 119 publications

(73 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In support of extensive prior clinical and incidence surveys, we also found that Type II tumors are diagnosed more often among older and non-white women [8,[15][16][17][18][19][20]. These differences in risk factor relationships, in combination with the more frequent occurrence of Type II cancers after menopause, provide some of the strongest epidemiologic support that endometrial cancers are etiologically heterogeneous.…”

Section: Discussionsupporting

confidence: 77%

Etiologic heterogeneity in endometrial cancer: Evidence from a Gyneco- logic Oncology Group trial

Brinton

Felix

Sherman

et al. 2013

Gynecologic Oncology

View full text Add to dashboard Cite

Objective-Although the epidemiology of typical endometrial carcinomas (grades 1-2 endometrioid or Type I) is well established, less is known regarding higher grade endometrioid or non-endometrioid carcinomas (Type II). Within a large Gynecologic Oncology Group trial (GOG-210), which included central pathology review, we investigated the etiologic heterogeneity of endometrial cancers by comparing risk factors for different histologic categories.Methods-Based on epidemiologic questionnaire data, risk factor associations, expressed as odds ratios (OR) with 95% confidence intervals (CI), were estimated comparing grade 3 endometrioid and Type II cancers (including histologic subtypes) to grades 1-2 endometrioid cancers. Results-Compared NIH Public Access

show abstract

Section: Discussionsupporting

confidence: 77%

Etiologic heterogeneity in endometrial cancer: Evidence from a Gyneco- logic Oncology Group trial

Brinton

Felix

Sherman

et al. 2013

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Unlike endometrioid carcinomas, aggressive endometrial carcinoma types, particularly serous carcinomas (14), may metastasize despite limited tumor volume in the uterus. Notably, "minimal uterine serous carcinoma" (15), which comprises approximately 20% of serous tumors (14,16), has been found to present with extra-uterine disease in up to 45% of women (17).…”

Section: Discussionmentioning

confidence: 99%

“…Notably, "minimal uterine serous carcinoma" (15), which comprises approximately 20% of serous tumors (14,16), has been found to present with extra-uterine disease in up to 45% of women (17). Further, molecular analysis in these cases suggests that intraand extra-uterine tumor cells are often clonally related (18)(19)(20)(21).…”

Section: Discussionmentioning

confidence: 99%

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial

Felix

Brinton

McMeekin

et al. 2015

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

Background: Stage is a critical determinant of treatment among endometrial carcinoma patients; understanding patterns of tumor spread may suggest approaches to improve staging. Specifically, the importance of exfoliation of endometrial carcinoma cells through the fallopian tubes into the peritoneum is ill defined. We assessed the hypothesis that tubal ligation (TL), which should impede transtubal passage of cells, is associated with lower endometrial carcinoma stage at presentation and, consequently, lower mortality.

show abstract

“…Slomovitz et al and Fader et al demonstrated that mixed histology and any percentage of USC in a mixedhistology specimen confer a risk for recurrence similar to that in a pure serous tumour. 6,26 We found no difference in prognosis between pure or mixed-histology USCs.…”

Section: Discussionmentioning

confidence: 56%

Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women

Pol

Allen

Bekkers

et al. 2015

Southern African Journal of Gynaecological Oncology

View full text Add to dashboard Cite

An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)

Cited by 119 publications

References 14 publications

Etiologic heterogeneity in endometrial cancer: Evidence from a Gyneco- logic Oncology Group trial

Etiologic heterogeneity in endometrial cancer: Evidence from a Gyneco- logic Oncology Group trial

Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial

Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women

Contact Info

Product

Resources

About